Emisphere’s Oral Insulin Candidate
Delivers unaltered insulin
No membrane permeablizers
Favorable kinetics consistently demonstrated
- EMISPHERE® delivery agent manufacturing scaled up
- EMISPHERE® delivery agent safety demonstrated in 90-day primate studies
- Pursue Type I and Type II therapy